| Budget Amount *help |
¥208,910,000 (Direct Cost: ¥160,700,000、Indirect Cost: ¥48,210,000)
Fiscal Year 2012: ¥32,760,000 (Direct Cost: ¥25,200,000、Indirect Cost: ¥7,560,000)
Fiscal Year 2011: ¥32,760,000 (Direct Cost: ¥25,200,000、Indirect Cost: ¥7,560,000)
Fiscal Year 2010: ¥32,760,000 (Direct Cost: ¥25,200,000、Indirect Cost: ¥7,560,000)
Fiscal Year 2009: ¥41,080,000 (Direct Cost: ¥31,600,000、Indirect Cost: ¥9,480,000)
Fiscal Year 2008: ¥69,550,000 (Direct Cost: ¥53,500,000、Indirect Cost: ¥16,050,000)
|
|---|
| Research Abstract |
The aim of this research project is rational design and development of cooperative multimetallic catalysts based on detailed mechanistic analysis, and their application to the enantioselective synthesis of therapeutics. A number of novel catalytic asymmetric reactions have been revealed through the identification of new multimetallic catalysts based on three different chiral ligand platforms. The synthetic utility of these catalysts culminated in the enantioselective synthesis of phamaceuticals including tamiflu, relenza, and lipitor.
|
